Generic Trilipix Capsules Launch

Released: 08/01/2013   By: Amanda Lafon, Executive Assistant

On July 15, 2013, Global Pharmaceuticals received final FDA approval and commenced shipping for generic Trilipix capsules (fenofibric acid). Abbott’s branded product Trilipix capsules had annual U.S. brand sales of approximately $554M for the 12 months ending March 31, 2013, according to IMS Health.

Trilipix capsules are indicated as an adjunct to diet in combination with a statin to reduce triglyceride and increase high-density lipoprotein cholesterol in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal.